Norrin Protein Modulation of Junction Proteins for Edema Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and cancer-related edema associated with compromised endothelial and epithelial cell junctions are limited in efficacy and have side effects, and there is a need to enhance the production of cadherin and claudin-5 to restore tight junction function.
Innovation Solution
A norrin-based substance, comprising an N-terminus norrin truncate or mutant with improved biological half-life, is used to bind to frizzled-4 receptors in endothelial or epithelial cells, promoting the expression and production of VE-cadherin and claudin-5 to tighten intercellular junctions and reduce edema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroidal or non-steroidal anti-inflammatories are used to treat tight junction failure, then inflammation is reduced, but efficacy is limited and side effects occur
Solution Approach 1:
The patent uses norrin protein as an intermediary substance that binds to Frizzled-4 receptors on endothelial and epithelial cells to directly restore tight junction function. This mediator approach bypasses the need for anti-inflammatory drugs, directly addressing the root cause (tight junction failure) rather than merely reducing inflammation symptoms, thereby improving efficacy while avoiding side effects associated with conventional anti-inflammatory therapies
Solution Approach 2:
The patent converts the harmful effect of VEGF-induced tight junction disruption into a beneficial treatment pathway by using norrin protein to activate Frizzled-4 receptors, which triggers downstream signaling that restores cadherin and claudin-5 expression. This transforms the pathological mechanism into a therapeutic opportunity, improving treatment reliability without the harmful side effects of conventional anti-inflammatory agents
2Reliability
If VEGF is over-expressed to compensate for lack of oxygen and nutrients, then tissue survival is improved, but vessel permeability increases due to depletion of adhesion molecules
Solution Approach 1:
The patent changes the physiological parameters by introducing norrin protein that binds to Frizzled-4 receptors, altering the signaling pathway downstream of VEGF. This modulation restores the expression levels of adhesion molecules (cadherin and claudin-5) without suppressing VEGF activity, thereby maintaining tissue survival benefits while correcting the harmful increase in vessel permeability through parameter optimization
3Productivity
If tight junctions are disrupted to allow cancer cell metastasis, then cancer progression occurs, but junctional integrity is compromised
Solution Approach 1:
The patent introduces norrin protein as a selective mediator that binds to Frizzled-4 receptors to restore tight junction integrity in normal endothelial and epithelial cells. This targeted approach preserves junctional stability in healthy tissues without interfering with cancer cell biology, thereby maintaining the natural progression dynamics while protecting normal tissue architecture through selective mediation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The norrin-based substance effectively increases the expression of claudin-5 and VE-cadherin, restoring tight junctions and reducing edema, particularly in conditions like Crohn's disease and retinal vasculature edema, with enhanced efficacy compared to anti-VEGF therapies.
Implementation Method 1
norrin protein; binding to frizzled-4 receptor of an endothelial or epithelial cell
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of tightening inter-cellular junctions in endothelial or epithelial cells includes exposing the endothelial or epithelial cells cells to norrin. Upon sufficient contact time, for norrin to selectively up- regulate gene expression of Cadherin or claudin-5 in the endothelial or epithelial cells, the inter-cellular junctions are tightened.